JSH practical guidelines for hematological malignancies, 2023: II. lymphoma 9—adult T-cell leukemia–lymphoma (ATL)
Authors:
Open Access
- 4 June 2025
- journal article
- guideline
- Published by Springer Nature in International Journal of Hematology
- Vol. 122 (2) , 177-189
Abstract
No abstract availableKeywords
Funding Information
- Kumamoto University
This publication has 38 references indexed in Scilit:
- Cord blood transplantation with a reduced-intensity conditioning regimen using fludarabine and melphalan for adult T-cell leukemia/lymphomaInternational Journal of Hematology, 2021
- The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantationHematological Oncology, 2018
- EPOCH regimen as salvage therapy for adult T-cell leukemia–lymphomaInternational Journal of Hematology, 2018
- Treatment of Patients with Adult T Cell Leukemia/Lymphoma with Cord Blood Transplantation: A Japanese Nationwide Retrospective SurveyTransplantation and Cellular Therapy, 2014
- Treatment outcome of elderly patients with aggressive adult T cell leukemia-lymphoma: Nagasaki University Hospital experienceInternational Journal of Hematology, 2014
- Feasibility of cord blood transplantation in chemosensitive adult T-cell leukemia/lymphoma: a retrospective analysis of the Nagasaki Transplantation NetworkInternational Journal of Hematology, 2013
- Unrelated cord blood transplantation for patients with adult T-cell leukemia/lymphoma: experience at a single instituteInternational Journal of Hematology, 2012
- Allogeneic Bone Marrow Transplantation from Unrelated Human T-Cell Leukemia Virus-I–negative Donors for Adult T-Cell Leukemia/Lymphoma: Retrospective Analysis of Data from the Japan Marrow Donor ProgramTransplantation and Cellular Therapy, 2007
- Deoxycoformycin-Containing Combination Chemotherapy for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study (JCOG9109)International Journal of Hematology, 2003
- Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine)Cancer, 1993